Multisystem Inflammatory Syndrome in a Pediatric Patient With Sickle Cell Disease and COVID-19: A Case Report

J Pediatr Hematol Oncol. 2022 Jan 1;44(1):e134-e137. doi: 10.1097/MPH.0000000000002191.

Abstract

To this day, there are limited data about the effects and management of coronavirus disease infection in pediatric patients with sickle cell disease. We present the management and successful clinical course of an 8-year-old female with homozygous sickle cell disease (SS) and severe acute chest syndrome secondary to coronavirus disease 2019 infection, complicated by cortical vein thrombosis.

Publication types

  • Case Reports

MeSH terms

  • Anemia, Sickle Cell / complications*
  • Anemia, Sickle Cell / pathology
  • Anemia, Sickle Cell / therapy
  • Anti-Bacterial Agents / therapeutic use
  • Azithromycin / therapeutic use
  • COVID-19 / complications*
  • COVID-19 / pathology
  • COVID-19 / therapy
  • Ceftriaxone / therapeutic use
  • Child
  • Erythrocyte Transfusion
  • Female
  • Humans
  • Intensive Care Units
  • Systemic Inflammatory Response Syndrome / complications*
  • Systemic Inflammatory Response Syndrome / pathology
  • Systemic Inflammatory Response Syndrome / therapy

Substances

  • Anti-Bacterial Agents
  • Ceftriaxone
  • Azithromycin

Supplementary concepts

  • pediatric multisystem inflammatory disease, COVID-19 related